Modified urokinase-type plasminogen activator polypeptides and methods of use
Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA pol...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Furfine, Eric Steven Way, Jeffrey Charles Tipton, Kimberly Traylor, Matthew John Thanos, Christopher Madison, Edwin L Soros, Vanessa Popkov, Mikhail |
| description | Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US11613744B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US11613744B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US11613744B23</originalsourceid><addsrcrecordid>eNqNyjEOwjAMQNEsDAi4gzlAh9AKdhCIpRMwV1bjgEUaW3WKxO1h4ABMf3h_7tpWAkemANMoT85oVJW3EmhCGzjLnTJgX_iFRUZQSV_UwoEMMAcYqDwkGEiEyWjpZhGT0erXhVufjtfDuSKVjkyxp0ylu1283_p61zT7Tf3P8wFHsTcU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Modified urokinase-type plasminogen activator polypeptides and methods of use</title><source>esp@cenet</source><creator>Furfine, Eric Steven ; Way, Jeffrey Charles ; Tipton, Kimberly ; Traylor, Matthew John ; Thanos, Christopher ; Madison, Edwin L ; Soros, Vanessa ; Popkov, Mikhail</creator><creatorcontrib>Furfine, Eric Steven ; Way, Jeffrey Charles ; Tipton, Kimberly ; Traylor, Matthew John ; Thanos, Christopher ; Madison, Edwin L ; Soros, Vanessa ; Popkov, Mikhail</creatorcontrib><description>Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230328&DB=EPODOC&CC=US&NR=11613744B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230328&DB=EPODOC&CC=US&NR=11613744B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Furfine, Eric Steven</creatorcontrib><creatorcontrib>Way, Jeffrey Charles</creatorcontrib><creatorcontrib>Tipton, Kimberly</creatorcontrib><creatorcontrib>Traylor, Matthew John</creatorcontrib><creatorcontrib>Thanos, Christopher</creatorcontrib><creatorcontrib>Madison, Edwin L</creatorcontrib><creatorcontrib>Soros, Vanessa</creatorcontrib><creatorcontrib>Popkov, Mikhail</creatorcontrib><title>Modified urokinase-type plasminogen activator polypeptides and methods of use</title><description>Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyjEOwjAMQNEsDAi4gzlAh9AKdhCIpRMwV1bjgEUaW3WKxO1h4ABMf3h_7tpWAkemANMoT85oVJW3EmhCGzjLnTJgX_iFRUZQSV_UwoEMMAcYqDwkGEiEyWjpZhGT0erXhVufjtfDuSKVjkyxp0ylu1283_p61zT7Tf3P8wFHsTcU</recordid><startdate>20230328</startdate><enddate>20230328</enddate><creator>Furfine, Eric Steven</creator><creator>Way, Jeffrey Charles</creator><creator>Tipton, Kimberly</creator><creator>Traylor, Matthew John</creator><creator>Thanos, Christopher</creator><creator>Madison, Edwin L</creator><creator>Soros, Vanessa</creator><creator>Popkov, Mikhail</creator><scope>EVB</scope></search><sort><creationdate>20230328</creationdate><title>Modified urokinase-type plasminogen activator polypeptides and methods of use</title><author>Furfine, Eric Steven ; Way, Jeffrey Charles ; Tipton, Kimberly ; Traylor, Matthew John ; Thanos, Christopher ; Madison, Edwin L ; Soros, Vanessa ; Popkov, Mikhail</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US11613744B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>Furfine, Eric Steven</creatorcontrib><creatorcontrib>Way, Jeffrey Charles</creatorcontrib><creatorcontrib>Tipton, Kimberly</creatorcontrib><creatorcontrib>Traylor, Matthew John</creatorcontrib><creatorcontrib>Thanos, Christopher</creatorcontrib><creatorcontrib>Madison, Edwin L</creatorcontrib><creatorcontrib>Soros, Vanessa</creatorcontrib><creatorcontrib>Popkov, Mikhail</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Furfine, Eric Steven</au><au>Way, Jeffrey Charles</au><au>Tipton, Kimberly</au><au>Traylor, Matthew John</au><au>Thanos, Christopher</au><au>Madison, Edwin L</au><au>Soros, Vanessa</au><au>Popkov, Mikhail</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Modified urokinase-type plasminogen activator polypeptides and methods of use</title><date>2023-03-28</date><risdate>2023</risdate><abstract>Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US11613744B2 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A37%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Furfine,%20Eric%20Steven&rft.date=2023-03-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS11613744B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |